gastroparesis glp 1 agonist Diabetic GLP-1 Manufacturers Argue Gastroparesis Lawsuits

Upper respiratory tract infections (URTIs) were the most frequently reported adverse event (8 of 12 reporting studies, 66.7%), occurring at rates comparable to controls across RCTs (GRADE: MODERATE certainty)

hazard ratio 1.60, 95% CI 1.37 to 1.87) but not after confounding factors were accounted for (0.91, 0.73 to 1.12)

Glucagon-like-peptide-1 receptor agonists (GLP-1s) have transformed weight management and treatment of chronic disease

Alpha-Lipoic Acid (ALA) adds antioxidant and metabolic support, assisting the bodys ability to utilize glucose more efficiently and support cellular energy production.*

For best results, we recommend 3-6 months of consistent daily use